SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Ryvu Therapeutics to Present Preclinical RVU602 and ONCO Prime Data

Ryvu Therapeutics says it will present preclinical data on RVU602, a novel ADC payload, and its ONCO Prime platform at the 2026 EORTC-NCI-AACR Symposium.

Related stories